Treats infections caused by susceptible isolates of the designated microorganisms in the…. ANDA 205548, held by Dr Reddys. Ciprofloxacin; Dexamethasone.
As of Nov 16, 2026, ANDA 205548 (Ciprofloxacin And Dexamethasone), held by Dr Reddys, was first approved by FDA on Aug 10, 2020, with 1 approved supplement and 0 published complete response letters.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa. Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 10, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ciprofloxacin And Dexamethasone0.3%;0.1% · suspension/drops;otic | Ciprofloxacin; Dexamethasone | Rx |
| Jul 9, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 10, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters